Ann Lab Med.  2015 Jul;35(4):410-415. 10.3343/alm.2015.35.4.410.

Characterization of Mucoid and Non-Mucoid Streptococcus pneumoniae Isolated From Outpatients

• Ogihara S
• Saito R
• Akikura T
• Iwama A
• Adachi Y
• Kaji D
• Kakinuma K
• Takahashi

• KMID: 2045863
• DOI: http://doi.org/10.3343/alm.2015.35.4.410

Abstract

BACKGROUND
Streptococcus pneumoniae causes pneumonia, sepsis, and meningitis. This study aimed to investigate the clinical characteristics of mucoid and non-mucoid isolates of S. pneumoniae, and to explore the relationship between the isolate phenotypes and their antibiotic susceptibility.
METHODS
Clinical isolates from 3,453 non-repetitive S. pneumoniae (189 mucoid and 3,264 non-mucoid) infections obtained between January 2008 and December 2012 from outpatients at the Kimitsu-Central Hospital were evaluated.
RESULTS
Compared to the non-mucoid isolates, the mucoid phenotypes were more susceptible to certain antibiotics such as erythromycin, clarithromycin, and tetracycline as opposed to clindamycin, chloramphenicol, and rifampicin. The mucoid phenotype was isolated more frequently from schoolchildren, adults, and elderly adults in a variety of clinical sites, including otorrhea, genitalia, pus, and eye discharge than the non-mucoid phenotype. This suggested that mucoid isolates are more likely to be involved than non-mucoid isolates in various local infections. Systemic infection, which indicates invasiveness, was not associated with the mucoid or non-mucoid phenotype.
CONCLUSIONS
The results of this study suggest that mucoid isolates tend to have higher susceptibility than non-mucoid isolates to antibiotics. To the best of our knowledge, mucoid and non-mucoid S. pneumoniae isolates considerably differ in terms of clinical isolation site and age-specific prevalence.

Keyword

Streptococcus pneumoniae; Mucoid colony; Antimicrobial susceptibility

MeSH Terms

Adult
Aged
Anti-Bacterial Agents
Chloramphenicol
Clarithromycin
Clindamycin
Erythromycin
Genitalia
Humans
Meningitis
Outpatients*
Phenotype
Pneumonia
Prevalence
Rifampin
Sepsis
Streptococcus pneumoniae*
Suppuration
Tetracycline
Anti-Bacterial Agents
Chloramphenicol
Clarithromycin
Clindamycin
Erythromycin
Rifampin
Tetracycline

Reference

1. Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med. 1990; 88(5N):1N–8N. PMID: 2294759.

2. Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Sunakawa K, et al. Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan. Microb Drug Resist. 2013; 19:308–315. PMID: 23480525.

3. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2002; 50(Suppl):1–5. PMID: 12077153.

4. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004; 48:2101–2107. PMID: 15155207.

5. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist. 1995; 1:115–120. PMID: 9158743.

6. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Accuracy of phenotypic methods for identification of Streptococcus pneumoniae isolates included in surveillance programs. J Clin Microbiol. 2008; 46:2184–2188. PMID: 18495854.

7. Speert DP, Farmer SW, Campbell ME, Musser JM, Selander RK, Kuo S. Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis. J Clin Microbiol. 1990; 28:188–194. PMID: 2107198.

8. Ciofu O, Fussing V, Bagge N, Koch C, Høiby N. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother. 2001; 48:391–396. PMID: 11533004.

9. Versalovic J, Carroll KC, et al. Manual of clinical microbiology. 10th ed. Washington DC: American Society for Microbiology;2011. p. 331–349.

10. Clinical and Laboratory Standards Institute. Reference method for broth dilution antimicrobial susceptibility testing. Approved standard. M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute;2014.

11. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol. 1995; 33:2759–2762. PMID: 8567920.

12. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis. 1998; 177:368–377. PMID: 9466523.

13. Gryllos I, Tran-Winkler HJ, Cheng MF, Chung H, Bolcome R 3rd, Lu W, et al. Induction of group A Streptococcus virulence by a human antimicobial peptide. Proc Natl Acad Sci U S A. 2008; 105:16755–16760. PMID: 18936485.

14. Kakuta R, Yano H, Hidaka H, Miyazaki H, Irimada M, Oda K, et al. Severe acute otitis media caused by mucoid streptococcus pyogenes in a previously healthy adult. Tohoku J Exp Med. 2014; 232:301–304. PMID: 24727832.

15. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 1999; 43:2877–2880. PMID: 10582875.

16. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin Infect Dis. 1998; 26:590–595. PMID: 9524828.

17. Mason EO Jr, Lamberth LB, Kershaw NL, Prosser BL, Zoe A, Ambrose PG. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother. 2000; 45:623–631. PMID: 10797084.